Summit Therapeutics Inc. (SMMT)

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up – What’s Next?

AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

AstraZeneca Invests in Summit Therapeutics after Year of Speculation

Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China